Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 85

1.

The serum and cerebrospinal fluid pharmacokinetics of anakinra after intravenous administration to non-human primates.

Fox E, Jayaprakash N, Pham TH, Rowley A, McCully CL, Pucino F, Goldbach-Mansky R.

J Neuroimmunol. 2010 Jun;223(1-2):138-40. doi: 10.1016/j.jneuroim.2010.03.022. Epub 2010 Apr 24.

2.

Intravenous anakinra can achieve experimentally effective concentrations in the central nervous system within a therapeutic time window: results of a dose-ranging study.

Galea J, Ogungbenro K, Hulme S, Greenhalgh A, Aarons L, Scarth S, Hutchinson P, Grainger S, King A, Hopkins SJ, Rothwell N, Tyrrell P.

J Cereb Blood Flow Metab. 2011 Feb;31(2):439-47. doi: 10.1038/jcbfm.2010.103. Epub 2010 Jul 14.

3.

Pharmacokinetic modelling of interleukin-1 receptor antagonist in plasma and cerebrospinal fluid of patients following subarachnoid haemorrhage.

Gueorguieva I, Clark SR, McMahon CJ, Scarth S, Rothwell NJ, Tyrrell PJ, Hopkins SJ, Rowland M.

Br J Clin Pharmacol. 2008 Mar;65(3):317-25. Epub 2007 Sep 13. Erratum in: Br J Clin Pharmacol. 2008 Nov;66(5):754. Tyrell, Pippa J [corrected to Tyrrell, Pippa J].

4.

Interleukin-1 receptor antagonist penetrates human brain at experimentally therapeutic concentrations.

Clark SR, McMahon CJ, Gueorguieva I, Rowland M, Scarth S, Georgiou R, Tyrrell PJ, Hopkins SJ, Rothwell NJ.

J Cereb Blood Flow Metab. 2008 Feb;28(2):387-94. Epub 2007 Aug 8.

PMID:
17684519
5.

The plasma and cerebrospinal fluid pharmacokinetics of erlotinib and its active metabolite (OSI-420) after intravenous administration of erlotinib in non-human primates.

Meany HJ, Fox E, McCully C, Tucker C, Balis FM.

Cancer Chemother Pharmacol. 2008 Aug;62(3):387-92. Epub 2007 Oct 12.

PMID:
17932674
6.

Cerebrospinal Fluid Cytokines Correlate With Aseptic Meningitis and Blood-Brain Barrier Function in Neonatal-Onset Multisystem Inflammatory Disease: Central Nervous System Biomarkers in Neonatal-Onset Multisystem Inflammatory Disease Correlate With Central Nervous System Inflammation.

Rodriguez-Smith J, Lin YC, Tsai WL, Kim H, Montealegre-Sanchez G, Chapelle D, Huang Y, Sibley CH, Gadina M, Wesley R, Bielekova B, Goldbach-Mansky R.

Arthritis Rheumatol. 2017 Jun;69(6):1325-1336. doi: 10.1002/art.40055. Epub 2017 May 10.

PMID:
28118536
8.

Plasma and cerebrospinal fluid pharmacokinetics of the histone deacetylase inhibitor, belinostat (PXD101), in non-human primates.

Warren KE, McCully C, Dvinge H, Tjørnelund J, Sehested M, Lichenstein HS, Balis FM.

Cancer Chemother Pharmacol. 2008 Aug;62(3):433-7. Epub 2007 Oct 25.

PMID:
17960383
9.

Protein HESylation for half-life extension: synthesis, characterization and pharmacokinetics of HESylated anakinra.

Liebner R, Mathaes R, Meyer M, Hey T, Winter G, Besheer A.

Eur J Pharm Biopharm. 2014 Jul;87(2):378-85. doi: 10.1016/j.ejpb.2014.03.010. Epub 2014 Mar 27.

PMID:
24681396
10.

Penetration of SCH-39304, a new antifungal triazole, into cerebrospinal fluid of primates.

Walsh TJ, Lester-McCully C, Rinaldi MG, Wallace JE, Balis FM, Lee JW, Pizzo PA, Poplack DG.

Antimicrob Agents Chemother. 1990 Jun;34(6):1281-4.

11.

Plasma and cerebrospinal fluid pharmacokinetics of pemetrexed after intravenous administration in non-human primates.

Stapleton SL, Reid JM, Thompson PA, Ames MM, McGovern RM, McGuffey L, Nuchtern J, Dauser R, Blaney SM.

Cancer Chemother Pharmacol. 2007 Mar;59(4):461-6. Epub 2006 Jul 20.

PMID:
16855840
12.

Pharmacokinetics and toxicology of immunotoxins administered into the subarachnoid space in nonhuman primates and rodents.

Muraszko K, Sung C, Walbridge S, Greenfield L, Dedrick RL, Oldfield EH, Youle RJ.

Cancer Res. 1993 Aug 15;53(16):3752-7.

13.

The plasma and cerebrospinal fluid pharmacokinetics of the platinum analog satraplatin after intravenous administration in non-human primates.

Marcus L, Murphy R, Fox E, McCully C, Cruz R, Warren KE, Meyer T, McNiff E, Balis FM, Widemann BC.

Cancer Chemother Pharmacol. 2012 Jan;69(1):247-52. doi: 10.1007/s00280-011-1659-z. Epub 2011 Jun 26.

PMID:
21706317
14.

Cerebrospinal fluid pharmacokinetics of intraventricular and intravenous aziridinylbenzoquinone.

Zimm S, Collins JM, Curt GA, O'Neill D, Poplack DG.

Cancer Res. 1984 Apr;44(4):1698-701.

15.

Plasma and cerebrospinal fluid pharmacokinetics of valproic acid after oral administration in non-human primates.

Stapleton SL, Thompson PA, Ou CN, Berg SL, McGuffey L, Gibson B, Blaney SM.

Cancer Chemother Pharmacol. 2008 Apr;61(4):647-52. Epub 2007 May 31.

PMID:
17541590
16.

Plasma and cerebrospinal fluid pharmacokinetics of SU5416 after intravenous administration in nonhuman primates.

Renbarger J, Aleksic A, McGuffey L, Dauser R, Berg S, Blaney S.

Cancer Chemother Pharmacol. 2004 Jan;53(1):39-42. Epub 2003 Oct 9.

PMID:
14551735
17.

Gentamicin penetration into cerebrospinal fluid in experimental Haemophilus influenzae meningitis.

Smith AL, Daum RS, Siber GR, Scheifele DW, Syriopoulou VP.

Antimicrob Agents Chemother. 1988 Jul;32(7):1034-9.

18.

Increased level of serum interleukin-1 receptor antagonist subsequent to resolution of clinical symptoms in patients with West syndrome.

Yamanaka G, Kawashima H, Oana S, Ishida Y, Miyajima T, Kashiwagi Y, Hoshika A.

J Neurol Sci. 2010 Nov 15;298(1-2):106-9. doi: 10.1016/j.jns.2010.07.018.

PMID:
20807663
19.

Plasma and cerebrospinal fluid pharmacokinetics of thalidomide and lenalidomide in nonhuman primates.

Muscal JA, Sun Y, Nuchtern JG, Dauser RC, McGuffey LH, Gibson BW, Berg SL.

Cancer Chemother Pharmacol. 2012 Apr;69(4):943-7. doi: 10.1007/s00280-011-1781-y. Epub 2011 Nov 23.

20.

Plasma pharmacokinetics and cerebrospinal fluid penetration of hypericin in nonhuman primates.

Fox E, Murphy RF, McCully CL, Adamson PC.

Cancer Chemother Pharmacol. 2001;47(1):41-4.

PMID:
11221960

Supplemental Content

Support Center